Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Catalano, Maria Graziella ^a   Fortunati, Nicoletta ^c   Pugliese, Mariateresa ^a   Marano, Francesca ^a   Ortoleva, Loredana ^a   Poli, Roberta ^a   Asioli, Sofia ^a   Bandino, Andrea ^a   Palestini, Nicola ^a   Grange, Cristina ^b   Bussolati, Benedetta ^b   Boccuzzi, Giuseppe ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; ENTINOSTAT; HISTONE DEACETYLASE; PANOBINOSTAT; TRICHOSTATIN A; UVOMORULIN;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MEMBRANE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BETA CATENIN; CADHERINS; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; PROTEIN TRANSPORT; PYRIDINES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84863573728     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2970     Document Type: Article

References (39)

1. Thiery JP 2002 Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
2. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G 2010 Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med 31:215-226
3. Ringel MD 2009 Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16:361-366
4. Christofori G, Semb H 1999 The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24:73-76 (Pubitemid 29346577)
5. Nelson WJ, Nusse R 2004 Convergence of Wnt, β-catenin, and cadherin pathways. Science 303:1483-1487 (Pubitemid 38314410)
6. van Roy F, Berx G 2008 The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 65:3756-3788
7. Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M 2011 HDACi - going through the mechanisms. Front Biosci 16:340-359
8. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G 2004 Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89:1006-1009 (Pubitemid 38269924)
9. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G 2005 Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90:1383-1389 (Pubitemid 40463993)
10. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M, Boccuzzi G 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191:465-472 (Pubitemid 44830622)
11. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G 2007 Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14:839-845 (Pubitemid 350074071)
12. Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G 2012 Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 130:694-704
13. Kim NH, Kim SN, Kim YK 2011 Involvement of HDAC1 in Ecadherin expression in prostate cancer cells: its implication for cell motility and invasion. Biochem Biophys ResCommun404:915-921
14. Srivastava RK, Kurzrock R, Shankar S 2010 MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9:3254-3266
15. Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T 2010 Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 127:1332-1346
16. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341 (Pubitemid 352789529)
17. Hajra KM, Ji X, Fearon ER 1999 Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18:7274-7279 (Pubitemid 30032106)
18. Lee KA, Bindereif A, Green MR 1988 A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. Gene Anal Tech 5:22-31
19. Jacobs K, Feys L, Vanhoecke B, Van Marck V Bracke M 2011 P-cadherin expression reduces melanoma growth, invasion, and responsiveness to growth factors in nude mice. Eur J Cancer Prev 20:207-216
20. Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ, Vougiouklakis T 2007 E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol 29:54-60 (Pubitemid 46713481)
21. Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R, Georgii A, Birchmeier W, von Zur Mühlen A, Dralle H 1995 Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 80:2168-2172
22. Huang SH, Wu JC, Chang KJ, Liaw KY, Wang SM 1999 Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue. Thyroid 9:1095-1103
23. Soares P, Berx G, van Roy F, Sobrinho-Simões M 1997 E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 70:32-38
24. Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S 2001 Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 76:176-180 (Pubitemid 32240227)
25. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Põtter E, Brabant G, Georgii A 1997 Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501-2507
26. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F 1995 E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115 (Pubitemid 26007298)
27. Cavallaro U, Christofori G 2004 Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118-132 (Pubitemid 38198740)
28. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A 2000 The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84-89
29. Hardy RG, Vicente-Dueñ as C, González-Herrero I, Anderson C, Flores T, Hughes S, Tselepis C, Ross JA, Sánchez-García I 2007 Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol 171:1037-1046
30. Dong X, Korch C, Meinkoth JL 2011 Histone deacetylase inhibitors upregulate Rap1 GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer 18:301-310
31. Peinado H, Ballestar E, Esteller M, Cano A 2004 Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24:306-319 (Pubitemid 38010056)
32. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B 2006 Derangement of the Ecadherin/ catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191:581-587
33. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G 2001 β-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996 (Pubitemid 32221790)
34. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL 2002 Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814-1818 (Pubitemid 34615274)
35. Pesutić-Pisac V, Punda A, Gluncić I, Bedeković V, Pranić-Kragić A, Kunac N 2008 Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croat Med J 49:643-649
36. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A 2000 The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 13:882-887 (Pubitemid 30643836)
37. Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL 2011 A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One 6:e27308
38. Beck J, Fischer T, George D, Huber C, Calvo E, Atadja P, Peng B, Kwong C, Sharma S, Patnaik A 2005 Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of oral LBH589B: a novel histone deacetylase (HDAC) inhibitor. J Clin Oncol 23:3148
39. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L, Fusco A 2010 Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29:105-116